Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.Peer-Reviewed Original ResearchConceptsAdvanced endometrial cancerImproved overall survivalNational Cancer Data BaseOverall survivalHistologic gradeEndometrial cancerCox proportional hazards regressionPropensity scoreMultivariable subgroup analysisSignificant OS benefitGrade 1 patientsProportional hazards regressionKaplan-Meier estimatesLog-rank testLack of benefitOS benefitAdjuvant therapyStage IIIAStage IVAFIGO stageAdjuvant CRTHazards regressionTumor sizeRegional radiotherapySubgroup analysisConcurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme
Kole AJ, Park HS, Yeboa DN, Rutter CE, Corso CD, Aneja S, Lester-Coll NH, Mancini BR, Knisely JP, Yu JB. Concurrent chemoradiotherapy versus radiotherapy alone for “biopsy‐only” glioblastoma multiforme. Cancer 2016, 122: 2364-2370. PMID: 27172136, DOI: 10.1002/cncr.30063.Peer-Reviewed Original ResearchConceptsPropensity score-matched analysisConcurrent chemoradiotherapySignificant OS benefitOverall survivalGlioblastoma multiformeOS benefitUS National Cancer Data BaseMultivariable Cox proportional hazards regressionNational Cancer Data BaseCox proportional hazards regressionImproved overall survivalStandard postoperative therapyProportional hazards regressionMultivariable logistic regressionLog-rank testStandard of careChi-square testClinicopathologic predictorsPostoperative therapySurgical resectionImproved survivalMedian ageMultivariable analysisHazards regressionNational cohort